Small molecule modulators of cyclin-dependent kinases for cancer therapy

The majority of human malignancies have aberrancies in the Retinoblastoma (Rb) pathway. Loss in Rb function results from the phosphorylation and inactivation of Rb by the cyclin-dependent kinases (cdks), main regulators of cell cycle progression. Thus, modulators of cdks may have a role in the treatment of human malignancies. Flavopiridol, the first cdk modulator tested in clinical trials, demonstrates interesting preclinical features: cell cycle block, induction of apoptosis, promotion of differentiation, inhibition of angiogenic processes and modulation of transcriptional events. Initial clinical trials with infusional flavopiridol demonstrated activity in some patients with lymphomas and renal, colon gastric carcinomas. Main side effects were diarrhea and hypotension. Phase 2 trials with infusional flavopiridol, other schedules and combination with standard chemotherapies are ongoing. The second cdk modulator tested in clinical trials, UCN-01, is a PKC inhibitor that can also modulate cdk activity. Similar to flavopiridol, UCN-01 blocks cell cycle progression and promotes apoptosis. Moreover, UCN-01 may abrogate checkpoints induced by genotoxic stress due to inhibition of chk1 kinase. The first clinical trial of UCN-01 demonstrated very prolonged half-life (∼600 h), due to high binding affinity of UCN-01 to the human alpha-1-acid glycoprotein. Main side effects were headaches, vomiting, hypoxemia and hyperglycemia. Clinical activity was observed in some patients with melanoma and lymphoma. Trials of shorter infusions of UCN-01 or in combination with standard chemotherapeutic agents are ongoing. Although several important basic and clinical questions remain unanswered, development of cdk modulators is a reasonable strategy for cancer therapy.

[1]  I. Pollack,et al.  Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. , 1996, Journal of neurosurgery.

[2]  E. Vokes,et al.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Altorki,et al.  Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  E. Sausville,et al.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. , 1998, The Journal of clinical investigation.

[5]  A. Senderowicz,et al.  Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. , 1999, International Journal of Oncology.

[6]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[7]  I. Takahashi,et al.  UCN-01, a selective inhibitor of protein kinase C from Streptomyces. , 1987, The Journal of antibiotics.

[8]  J. Sarkaria,et al.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. , 1999, Cancer research.

[9]  D. Dean,et al.  Active Transcriptional Repression by the Rb–E2F Complex Mediates G1 Arrest Triggered by p16INK4a, TGFβ, and Contact Inhibition , 1999, Cell.

[10]  T. Tamaoki.  Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. , 1991, Methods in enzymology.

[11]  R. Weinberg,et al.  The role of RB in cell cycle control. , 1995, Progress in cell cycle research.

[12]  J. Takahara,et al.  UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. , 1996, Biochemical and biophysical research communications.

[13]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .

[14]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[16]  G. Schwartz,et al.  UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  I. Takahashi,et al.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. , 1989, The Journal of antibiotics.

[18]  Stephen J. Elledge,et al.  Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.

[19]  K. Kohn,et al.  Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.

[20]  E. Sausville,et al.  Preclinical and clinical development of cyclin-dependent kinase modulators. , 2000, Journal of the National Cancer Institute.

[21]  J. Gabrilove,et al.  The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. , 1997, Blood.

[22]  E. Sausville,et al.  UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. , 1996, Journal of the National Cancer Institute.

[23]  S H Kim,et al.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Verweij,et al.  Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[26]  S. Shousha,et al.  High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Nettelbeck,et al.  Cell cycle‐independent induction of apoptosis by the anti‐tumor drug flavopiridol in endothelial cells , 1998, International journal of cancer.

[28]  E. Sausville,et al.  Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.

[29]  J. Sarkaria,et al.  The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. , 2000, Cancer research.

[30]  W. Stadler,et al.  In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer , 1999, Cancer Chemotherapy and Pharmacology.

[31]  David S. Park,et al.  Inhibitors of Cyclin-dependent Kinases Promote Survival of Post-mitotic Neuronally Differentiated PC12 Cells and Sympathetic Neurons (*) , 1996, The Journal of Biological Chemistry.

[32]  L. Meijer,et al.  Chemical inhibitors of cyclin-dependent kinases , 1997 .

[33]  Wim H. M. Saris,et al.  Proceedings of the American Association for Cancer Research. , 2001 .

[34]  S. Akinaga,et al.  Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. , 1991, Cancer research.

[35]  Edward A. Sausville,et al.  The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01* , 2000, The Journal of Biological Chemistry.

[36]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[37]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[38]  E. Sausville,et al.  Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. , 1999, Cancer research.

[39]  L Meijer,et al.  Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. , 1999, Cancer research.

[40]  J. Pines,et al.  Cyclins and cyclin-dependent kinases: theme and variations. , 1995, Advances in cancer research.

[41]  S. Elledge,et al.  Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.

[42]  M. Grever,et al.  Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. , 1998, Blood.

[43]  A. Giordano,et al.  Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. , 1995, Critical reviews in eukaryotic gene expression.

[44]  H. Nakanishi,et al.  Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. , 1996, Oncology.

[45]  S. Kaufmann,et al.  Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. , 1996, Cancer research.

[46]  L Meijer,et al.  Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. , 1999, Pharmacology & therapeutics.

[47]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[48]  E. Sausville,et al.  Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication* , 2000, The Journal of Biological Chemistry.

[49]  E. Sausville,et al.  Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. , 1993, Cancer research.

[50]  E. Sausville,et al.  Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. , 1993, Biochemical pharmacology.

[51]  A. Hart,et al.  Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. , 1995, Cancer research.

[52]  R. Müller,et al.  Bcl-2 Independence of Flavopiridol-induced Apoptosis , 2000, The Journal of Biological Chemistry.

[53]  J. Jen,et al.  Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma , 1999, Oncogene.

[54]  G. Schwartz,et al.  UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  M. Shimizu,et al.  Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole. , 1999, Anti-cancer drugs.

[56]  Yiwei Li,et al.  Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  Ping Wei,et al.  A Novel CDK9-Associated C-Type Cyclin Interacts Directly with HIV-1 Tat and Mediates Its High-Affinity, Loop-Specific Binding to TAR RNA , 1998, Cell.

[58]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[59]  M. Urano,et al.  The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma. , 1997, International journal of radiation oncology, biology, physics.

[60]  S. Kaufmann,et al.  Antineoplastic Agents: the Importance of Sequence of Administration' , 2022 .

[61]  F. Sarkar,et al.  Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. , 2000, International journal of oncology.

[62]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[63]  E. Sausville,et al.  Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. , 1994, Molecular pharmacology.

[64]  John Calvin Reed,et al.  Protein Kinase Inhibitors Flavopiridol and 7-hydroxy-staurosporine Down-regulate Antiapoptosis Proteins in B-cell Chronic Lymphocytic Leukemia , 2022 .

[65]  A. Giordano,et al.  PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[66]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[67]  E. Sausville,et al.  UCN-01 Abrogates G2 Arrest through a Cdc2-dependent Pathway That Is Associated with Inactivation of the Wee1Hu Kinase and Activation of the Cdc25C Phosphatase* , 1998, The Journal of Biological Chemistry.

[68]  J. Milton,et al.  Identification of multiple cyclin subunits of human P-TEFb. , 1998, Genes & development.

[69]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.